 <h1>Nipent Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>pentostatin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about pentostatin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Nipent.</p><h2>In Summary</h2><p><b>Common side effects of Nipent include:</b> skin rash.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pentostatin: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Pentostatin should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. The use of doses higher than those specified is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used pentostatin at higher doses (20 to 50 mg/m(2) in divided doses over 5 days) than recommended. In a clinical investigation in patients with refractory chronic lymphocytic leukemia using pentostatin at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of pentostatin in combination with fludarabine phosphate is not recommended.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pentostatin (the active ingredient contained in Nipent) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pentostatin may cause some unwanted effects. Some side effects will have signs or symptoms that you can see or feel. Your doctor may watch for others by doing certain tests.</p><p>Also, because of the way these medicines act on the body, there is a chance that they might cause other unwanted effects that may not occur until months or years after the medicine is used. These delayed effects may include certain types of cancer. Discuss these possible effects with your doctor.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking pentostatin:</p><p>
<i>More common</i>
</p><ul>
<li>Cough or hoarseness</li>
<li>fever or chills</li>
<li>lower back or side pain</li>
<li>pain</li>
<li>painful or difficult urination</li>
<li>skin rash or itching (sudden)</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety or nervousness</li>
<li>black, tarry stools</li>
<li>blood in the urine or stools</li>
<li>changes in vision</li>
<li>chest pain</li>
<li>confusion</li>
<li>cramps in lower legs</li>
<li>mental depression</li>
<li>nosebleed</li>
<li>numbness or tingling of the hands or feet</li>
<li>pinpoint red spots on the skin</li>
<li>shortness of breath</li>
<li>sleepiness</li>
<li>sore, red eyes</li>
<li>sores in the mouth or on the lips</li>
<li>stomach pain</li>
<li>swelling of the feet or lower legs</li>
<li>trouble with sleeping</li>
<li>unusual bleeding or bruising</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pentostatin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
<li>headache</li>
<li>loss of appetite</li>
<li>muscle pain</li>
<li>nausea and vomiting</li>
<li>skin rash</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Back pain</li>
<li>bloating or gas</li>
<li>constipation</li>
<li>dry skin</li>
<li>general feeling of discomfort or illness</li>
<li>itching</li>
<li>joint pain</li>
<li>weakness</li>
<li>weight loss</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pentostatin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (22%), thrombocytopenia, anemia, blood disorder, eosinophilia, hypochromic pancytopenia</p>
<p><b>Common</b> (1% to 10%): Agranulocytosis, acute leukemia, febrile neutropenia, ecchymosis, lymphadenopathy, splenomegaly, hemorrhage, agranulocytosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Pure red cell aplasia, autoimmune hemolytic anemia, anemia-hemolytic, aplastic anemia hemolytic uremic syndrome, idiopathic thrombocytopenia purpura, thrombotic thrombocytopenia purpura</p>
<p><b>Rare</b> (less than 0.1%): Autoimmune thrombocytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea/vomiting (63%), diarrhea (17%), abdominal pain (16%), stomatitis (12%)</p>
<p><b>Common</b> (1% to 10%): Oral candidiasis, perianal abscess, dental abnormalities, dyspepsia, flatulence, gingivitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute gastroenteritis</p>
<p><b>Rare</b> (less than 0.1%): Esophageal candidiasis</p>
<p><b>Frequency not reported</b>: Constipation, dysphagia, glossitis, ileus<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (43%), pruritus (21%)</p>
<p><b>Common</b> (1% to 10%): Furunculosis, abscess skin, mycotic skin infection, sweating, skin disorder, face edema, dry skin urticaria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatic disorder, elevated liver function tests</p>
<p><b>Frequency not reported</b>: Kidney function abnormal, nephropathy<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Cystitis</p>
<p><b>Frequency not reported</b>: Amenorrhea, breast lump, impotence<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (20%), upper respiratory infection (13%), rhinitis (11%), dyspnea (11%), pharyngitis</p>
<p><b>Common</b> (1% to 10%): Sinusitis, pneumonia, bronchitis, E.  coli pneumonia, fungal pneumonia, asthma</p>
<p><b>Uncommon</b> (0.1% to 1%): Pulmonary aspergillosis, pulmonary aspergillosis</p>
<p><b>Frequency not reported</b>: Bronchospasm, larynx edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (17%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, paresthesia</p>
<p><b>Frequency not reported</b>: Amnesia, ataxia, convulsions, dysarthria, encephalitis, hyperkinesia, meningism, neuralgia, neuritis, neuropathy, paralysis, syncope, twitching, vertigo<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, hypotension</p>
<p><b>Frequency not reported</b>: Angina pectoris, arrhythmia, A-V block, bradycardia, extrasystoles ventricular, heart arrest, heart failure, hypertension, pericardial effusion, phlebitis, pulmonary embolus, sinus arrest, tachycardia, thrombophlebitis deep, vasculitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergic reaction</p>
<p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis</p>
<p><b>Frequency not reported</b>: Amblyopia, dry eyes, labyrinthitis, lacrimation disorder, nonreactive eye, photophobia, retinopathy, abnormal vision, watery eyes<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (19%)</p>
<p><b>Common</b> (1% to 10%): Osteomyelitis, arthralgia</p>
<p><b>Frequency not reported</b>: Arthritis, gout<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (13%)</p>
<p><b>Common</b> (1% to 10%): Neurologic disorder, CNS/CNS toxicity</p>
<p><b>Frequency not reported</b>: Hypercalcemia, hyponatremia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Viral infection</p>
<p><b>Common</b> (1% to 10%): (Herpes zoster, infection unspecified), cellulitis, bacterial infection, herpes simplex, sepsis, septic shock, staphylococcal infection, Graft versus host disease </p>
<p><b>Uncommon</b> (0.1% to 1%): Clostridium difficile colitis, cytomegalovirus infection, graft failure</p>
<p><b>Frequency not reported</b>: Influenza-like symptoms<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Confusion, insomnia, somnolence, anxiety, depression, nervousness</p>
<p><b>Frequency not reported</b>: decrease/loss libido, emotional lability, hallucination, hostility, neurosis, thinking abnormal, dreaming abnormal<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Neoplasms, skin carcinoma</p>
<p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome</p>
<p><b>Frequency not reported</b>: Acute leukemia, hemolytic anemia, aplastic anemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (46%), fatigue (42%), chills (19%), asthenia (12%)</p>
<p><b>Common</b> (1% to 10%): Pain, peripheral edema</p>
<p><b>Frequency not reported</b>: Hangover effect, deafness, earache, tinnitus, unusual taste<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urosepsis, elevated creatinine</p>
<p><b>Frequency not reported</b>: Renal failure, renal insufficiency, renal stone<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL. </p><p id="ref_2">2. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR "Immunosuppressive effects of pentostatin." J Clin Oncol 8 (1990): 848-55</p><p id="ref_3">3. Cheson BD "Infectious and immunosuppressive complications of purine analog therapy." J Clin Oncol 13 (1995): 2431-48</p><p id="ref_4">4. Sorensen JM, Chun HG, Vena D, Fallavollita A, Cheson BD "PENTOSTATIN (DCF) THERAPY FOR HAIRY CELL LEUKEMIA (HCL): UPDATE OF A GROUP C PROTOCOL OF 208 PATIENTS (PTS) WHO HAVE FAILED INTERFERON ALPHA (IFNA) (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a7871991</p><p id="ref_5">5. Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ "Pentostatin induces durable remissions in hairy cell leukemia." J Clin Oncol 9 (1991): 243-6</p><p id="ref_6">6. Grem JL, King SA, Chun HG, Grever MR "Cardiac complications observed in elderly patients following 2'- deoxycoformycin therapy." Am J Hematol 38 (1991): 245-7</p><p id="ref_7">7. Bruno JJ,  Canada TW "Possible pentostatin-induced symptomatic hyponatremia." Pharmacotherapy 27 (2007): 164-9</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Nipent (pentostatin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Generic Availability</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nipent &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hairy Cell Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pentostatin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Leukopenia (22%), thrombocytopenia, anemia, blood disorder, eosinophilia, hypochromic pancytopenia</p><p><b>Common</b> (1% to 10%): Agranulocytosis, acute leukemia, febrile neutropenia, ecchymosis, lymphadenopathy, splenomegaly, hemorrhage, agranulocytosis</p><p><b>Uncommon</b> (0.1% to 1%): Pure red cell aplasia, autoimmune hemolytic anemia, anemia-hemolytic, aplastic anemia hemolytic uremic syndrome, idiopathic thrombocytopenia purpura, thrombotic thrombocytopenia purpura</p><p><b>Rare</b> (less than 0.1%): Autoimmune thrombocytopenia<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea/vomiting (63%), diarrhea (17%), abdominal pain (16%), stomatitis (12%)</p><p><b>Common</b> (1% to 10%): Oral candidiasis, perianal abscess, dental abnormalities, dyspepsia, flatulence, gingivitis</p><p><b>Uncommon</b> (0.1% to 1%): Acute gastroenteritis</p><p><b>Rare</b> (less than 0.1%): Esophageal candidiasis</p><p><b>Frequency not reported</b>: Constipation, dysphagia, glossitis, ileus<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (43%), pruritus (21%)</p><p><b>Common</b> (1% to 10%): Furunculosis, abscess skin, mycotic skin infection, sweating, skin disorder, face edema, dry skin urticaria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Hepatic disorder, elevated liver function tests</p><p><b>Frequency not reported</b>: Kidney function abnormal, nephropathy<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Cystitis</p><p><b>Frequency not reported</b>: Amenorrhea, breast lump, impotence<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (20%), upper respiratory infection (13%), rhinitis (11%), dyspnea (11%), pharyngitis</p><p><b>Common</b> (1% to 10%): Sinusitis, pneumonia, bronchitis, E.  coli pneumonia, fungal pneumonia, asthma</p><p><b>Uncommon</b> (0.1% to 1%): Pulmonary aspergillosis, pulmonary aspergillosis</p><p><b>Frequency not reported</b>: Bronchospasm, larynx edema<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (17%)</p><p><b>Common</b> (1% to 10%): Dizziness, paresthesia</p><p><b>Frequency not reported</b>: Amnesia, ataxia, convulsions, dysarthria, encephalitis, hyperkinesia, meningism, neuralgia, neuritis, neuropathy, paralysis, syncope, twitching, vertigo<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest pain, hypotension</p><p><b>Frequency not reported</b>: Angina pectoris, arrhythmia, A-V block, bradycardia, extrasystoles ventricular, heart arrest, heart failure, hypertension, pericardial effusion, phlebitis, pulmonary embolus, sinus arrest, tachycardia, thrombophlebitis deep, vasculitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergic reaction</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Conjunctivitis</p><p><b>Frequency not reported</b>: Amblyopia, dry eyes, labyrinthitis, lacrimation disorder, nonreactive eye, photophobia, retinopathy, abnormal vision, watery eyes<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Myalgia (19%)</p><p><b>Common</b> (1% to 10%): Osteomyelitis, arthralgia</p><p><b>Frequency not reported</b>: Arthritis, gout<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (13%)</p><p><b>Common</b> (1% to 10%): Neurologic disorder, CNS/CNS toxicity</p><p><b>Frequency not reported</b>: Hypercalcemia, hyponatremia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Viral infection</p><p><b>Common</b> (1% to 10%): (Herpes zoster, infection unspecified), cellulitis, bacterial infection, herpes simplex, sepsis, septic shock, staphylococcal infection, Graft versus host disease </p><p><b>Uncommon</b> (0.1% to 1%): Clostridium difficile colitis, cytomegalovirus infection, graft failure</p><p><b>Frequency not reported</b>: Influenza-like symptoms<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Confusion, insomnia, somnolence, anxiety, depression, nervousness</p><p><b>Frequency not reported</b>: decrease/loss libido, emotional lability, hallucination, hostility, neurosis, thinking abnormal, dreaming abnormal<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Neoplasms, skin carcinoma</p><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome</p><p><b>Frequency not reported</b>: Acute leukemia, hemolytic anemia, aplastic anemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever (46%), fatigue (42%), chills (19%), asthenia (12%)</p><p><b>Common</b> (1% to 10%): Pain, peripheral edema</p><p><b>Frequency not reported</b>: Hangover effect, deafness, earache, tinnitus, unusual taste<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Urosepsis, elevated creatinine</p><p><b>Frequency not reported</b>: Renal failure, renal insufficiency, renal stone<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Nipent (pentostatin)." Hospira Inc, Lake Forest, IL. </p><p id="ref_2">2. Kraut EH, Neff JC, Bouroncle BA, Gochnour D, Grever MR "Immunosuppressive effects of pentostatin." J Clin Oncol 8 (1990): 848-55</p><p id="ref_3">3. Cheson BD "Infectious and immunosuppressive complications of purine analog therapy." J Clin Oncol 13 (1995): 2431-48</p><p id="ref_4">4. Sorensen JM, Chun HG, Vena D, Fallavollita A, Cheson BD "PENTOSTATIN (DCF) THERAPY FOR HAIRY CELL LEUKEMIA (HCL): UPDATE OF A GROUP C PROTOCOL OF 208 PATIENTS (PTS) WHO HAVE FAILED INTERFERON ALPHA (IFNA) (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a7871991</p><p id="ref_5">5. Cassileth PA, Cheuvart B, Spiers AS, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O'Connell MJ "Pentostatin induces durable remissions in hairy cell leukemia." J Clin Oncol 9 (1991): 243-6</p><p id="ref_6">6. Grem JL, King SA, Chun HG, Grever MR "Cardiac complications observed in elderly patients following 2'- deoxycoformycin therapy." Am J Hematol 38 (1991): 245-7</p><p id="ref_7">7. Bruno JJ,  Canada TW "Possible pentostatin-induced symptomatic hyponatremia." Pharmacotherapy 27 (2007): 164-9</p><h2>More about Nipent (pentostatin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Generic Availability</li>
<li>Drug class: antibiotics/antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Nipent &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hairy Cell Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>